Home/Pipeline/Preclinical Program 5

Preclinical Program 5

Not Disclosed

PreclinicalIND-Enabling

Key Facts

Indication

Not Disclosed

Phase

Preclinical

Status

IND-Enabling

Company

Adagene

About Adagene

Adagene's mission is to transform antibody drug discovery and development through its proprietary AI-powered Dynamic Precision Library (DPL) platform. The company has achieved significant validation through strategic collaborations with global pharmaceutical partners and has advanced a pipeline of nine candidates, including its lead SAFEbody-masked anti-CTLA-4 program, ADG126, which has shown a compelling clinical safety profile. Its strategy focuses on leveraging computational design to create precision biologics with enhanced therapeutic indices, aiming to deliver first- or best-in-class therapies in oncology while monetizing its platform through partnerships.

View full company profile

Therapeutic Areas

Oncology

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active